[go: up one dir, main page]

WO2009101684A1 - Médicament pour prévenir et/ou traiter une fusion viscérale - Google Patents

Médicament pour prévenir et/ou traiter une fusion viscérale Download PDF

Info

Publication number
WO2009101684A1
WO2009101684A1 PCT/JP2008/052393 JP2008052393W WO2009101684A1 WO 2009101684 A1 WO2009101684 A1 WO 2009101684A1 JP 2008052393 W JP2008052393 W JP 2008052393W WO 2009101684 A1 WO2009101684 A1 WO 2009101684A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
adhesion
lower alkyl
visceral
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052393
Other languages
English (en)
Japanese (ja)
Inventor
Koichi Shudo
Naoko Katsumura
Miwako Ishido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEMPHYS Ltd
Original Assignee
KEMPHYS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEMPHYS Ltd filed Critical KEMPHYS Ltd
Priority to PCT/JP2008/052393 priority Critical patent/WO2009101684A1/fr
Priority to JP2009553303A priority patent/JPWO2009101684A1/ja
Publication of WO2009101684A1 publication Critical patent/WO2009101684A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a medicament for prevention and / or treatment of visceral adhesion in peritoneal dialysis therapy or adhesive ileus (intestinal obstruction) after surgery.
  • Adhesion is a biological phenomenon in which tissues or organs that are originally separated medically are joined together to form scar tissue between them.
  • gastroenterology, cardiology, orthopedics, gynecology, or ophthalmology May occur after surgery in each department, or may occur in the form of adhesion between the intestinal walls or adhesion between the intestinal wall and the abdominal wall at the onset of inflammatory bowel disease.
  • Adhesion occurs due to an inflammatory reaction, trauma, surgery, or the like, but is originally considered one of the wound healing processes.
  • excessive adhesions cause disorders such as pain, bowel obstruction (ileus), or infertility.
  • severe adhesions are a factor that complicates re-opening surgery, which is an important medical problem.
  • intraperitoneal adhesion may be a problem even in patients with peritoneal dialysis (CAPD).
  • CAPD peritoneal dialysis
  • This CAPD therapy is a treatment method for patients with renal failure, and its advantage is recognized as one of home medical care.
  • intra-abdominal tissue adhesions that is, adhesions to the intestinal tract and the abdominal wall, occur as complications, they exhibit advanced passage obstruction in the intestinal tract and further reduce the dialysis effect, so it is unavoidable to discontinue CAPD therapy.
  • an anti-adhesion film (trade name Sepra film) based on polysaccharides (such as hyaluronic acid) has been put into practical use.
  • polysaccharides such as hyaluronic acid
  • the anti-adhesion film and the polymer polysaccharide solution are expensive.
  • some kind of pharmacotherapy is strongly desired for an adhesion site such as a serious adhesion or intestinal lumen side, but an inexpensive and effective drug for preventing or treating the adhesion has not been developed.
  • retinoic acid (vitamin A acid) is an active metabolite of vitamin A, and has the effect of differentiating developing immature cells into mature cells with specific functions, cell growth promotion and life support. It has extremely important physiological actions such as.
  • vitamin A derivatives synthesized so far, for example, benzoic acid derivatives described in JP-A-61-22047 and JP-A-61-76440, and Journal of Medicinal Chemistry (Journal of Medicinal Chemistry) , 1988, Vol. 31, No. 11, p. 2182) have been shown to have similar physiological effects.
  • the above compounds having retinoic acid and retinoic acid-like biological activity are collectively referred to as “retinoids”.
  • retinoic acid-like biological activity for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl] benzoic acid: tamibarotene
  • Is also suggested to bind to RAR as well as retinoic acid to exert physiological activity (Hashimoto, Y., Cell struct. Funct., 16, pp.113-123, 1991; Hashimoto, Y., et al., Biochem. Biophys. Res. Commun., 166, pp. 1300-1307, 1990.
  • These compounds have been found clinically useful for the treatment and prevention of vitamin A deficiency, epithelial keratosis, rheumatism, delayed allergy, bone disease, and leukemia and certain cancers. ing.
  • An object of the present invention is to provide a medicine capable of exerting a preventive and / or therapeutic effect on visceral adhesion by systemic administration.
  • the present invention provides a medicament capable of achieving an excellent preventive and / or therapeutic effect by systemic administration for post-surgical adhesion, intraperitoneal adhesion by peritoneal dialysis, adhesive ileus (intestinal obstruction), and Usherman syndrome. It is a problem.
  • a medicament for systemic administration for the prevention and / or treatment of visceral adhesion the following general formula (I): [Wherein, R 1 , R 2 , R 3 , R 4 , and R 5 each independently represent a hydrogen atom, a lower alkyl group, or a lower alkyl-substituted silyl group, and R 1 , R 2 , R 3 , R 4 And any two adjacent groups of R 5 are lower alkyl groups, they together form a 5- or 6-membered ring with the carbon atom on the benzene ring to which they are attached.
  • the ring may have one or more alkyl groups
  • X represents —CONH— or —NHCO—
  • A represents an optionally substituted carboxylic acid-substituted fragrance.
  • a troponyl group which may have a group or a substituent]] or a salt thereof as an active ingredient.
  • the above medicament wherein the visceral adhesion is post-surgical adhesion, intraperitoneal adhesion by peritoneal dialysis, adhesive ileus, or Asherman syndrome, and the above-mentioned medicament in which systemic administration is oral administration.
  • the visceral adhesion is post-surgical adhesion, intraperitoneal adhesion by peritoneal dialysis, adhesive ileus, or Asherman syndrome, and the above-mentioned medicament in which systemic administration is oral administration.
  • Another aspect is the use of a compound represented by the above general formula (I) or a salt thereof for the manufacture of the above-mentioned medicament; and a method for preventing and / or treating visceral adhesion,
  • a method comprising the step of systemic administration, preferably oral administration, of an effective amount of the compound represented by I) or a salt thereof to a mammal including human.
  • the medicament of the present invention is useful as a medicament for prevention and / or treatment of visceral adhesion such as postoperative adhesion, intraperitoneal adhesion by peritoneal dialysis, adhesive ileus, or Asherman syndrome, and systemic administration, preferably oral It has the feature that an extremely high prophylactic and / or therapeutic effect can be exhibited by administration.
  • the lower alkyl group represented by R 1 , R 2 , R 3 , R 4 , and R 5 has about 1 to 6 carbon atoms, preferably 1 to 1 carbon atoms.
  • Four linear or branched alkyl groups can be used.
  • a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, or a tert-butyl group can be used.
  • One or more arbitrary substituents may be present on the lower alkyl group. Examples of the substituent include a hydroxyl group, a lower alkoxy group, and a halogen atom.
  • Examples of the lower alkyl-substituted silyl group represented by R 1 , R 2 , R 3 , R 4 , and R 5 include a trimethylsilyl group.
  • Two adjacent lower alkyl groups selected from the group consisting of R 1 , R 2 , R 3 , R 4 , and R 5 are joined together to form a 5-membered ring or 6 together with the carbon atom on the benzene ring to which they are bonded.
  • One or two member rings may be formed, preferably one.
  • the ring thus formed may be saturated, partially saturated, or aromatic, and may have one or more alkyl groups on the ring.
  • As the alkyl group which can be substituted on the ring a linear or branched alkyl group having about 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, can be used.
  • a methyl group, an ethyl group or the like can be used, and preferably 2 to 4 methyl groups, more preferably 4 methyl groups may be substituted.
  • R 2 and the benzene ring and R 2 and R 3 wherein R 3 is substituted, 5,6,7,8-tetrahydronaphthalene ring or 5,5,8,8-tetramethyl--5,6,7, An 8-tetrahydronaphthalene ring or the like is preferably formed.
  • carboxylic acid-substituted aromatic group represented by A a carboxylic acid-substituted phenyl group or a carboxylic acid-substituted heterocyclic group can be used, but a carboxylic acid-substituted phenyl group is preferable, and a 4-carboxyphenyl group is more preferable.
  • heterocyclic carboxylic acid constituting the carboxylic acid substituted heterocyclic group represented by A include pyrimidine-5-carboxylic acid.
  • the tropolonyl group represented by A is preferably a tropolon-5-yl group.
  • One or more other substituents may be present on the ring of these carboxylic acid-substituted aromatic groups or troponyl groups.
  • substituent is not specifically limited, For example, a hydroxyl group, a halogen atom, an amino group etc. can be illustrated.
  • a compound having a phenyl-substituted carbamoylbenzoic acid or a phenyl-substituted carboxamide benzoic acid as a basic skeleton can be used.
  • 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl] benzoic acid (Hashimoto) is a typical example of a compound having a phenyl-substituted carbamoylbenzoic acid as a basic skeleton. , Y., Cell struct.
  • a salt of the above compound may be used.
  • physiologically acceptable salts such as metal salts such as sodium salt, potassium salt, magnesium salt, or calcium salt, ammonium salts, or organic amine salts such as triethylamine salt or ethanolamine salt are effective for the pharmaceutical of the present invention. It can be used as a component.
  • a prodrug of the above compound may be used as an active ingredient of the medicament of the present invention.
  • a prodrug is a compound or salt thereof that undergoes a change such as hydrolysis in vivo, preferably in blood, after systemic administration to a mammal orally or parenterally to produce a compound or salt thereof. .
  • prodrug of the compound or a salt thereof is not particularly limited.
  • a prodrug obtained by converting the carboxyl group to an alkoxycarbonyl group is exemplified.
  • Preferable examples include ester compounds such as methoxycarbonyl group or ethoxycarbonyl group.
  • the above compounds may have one or more asymmetric carbons depending on the type of substituent, and any optical isomer based on these asymmetric carbons, any mixture of optical isomers, Racemates, diastereoisomers based on two or more asymmetric carbons, any mixture of diastereoisomers, and the like can be used as the active ingredients of the medicament of the present invention.
  • geometric isomers based on cis or trans bonds of double bonds, and any mixtures of geometric isomers, and any hydrates or solvates of compounds in the form of free compounds or salts are also included in the medicament of the present invention. It can be used as an active ingredient.
  • Visceral adhesions to which the pharmaceutical of the present invention is applied include adhesions that develop after surgery, inflammatory bowel disease, irritable bowel syndrome, duodenal ulcers, acute enterocolitis, protein-losing enteropathy, colon cancer, appendicitis, Examples include, but are not limited to, adhesive ileus (intestinal obstruction) caused by hemorrhagic colitis, intestinal tuberculosis, intestinal Behcet, or colonic diverticulosis, intraperitoneal adhesion by peritoneal dialysis, or uterine adhesion by Asherman syndrome There is no.
  • the medicament of the present invention contains one or more substances selected from the group consisting of the above retinoids and salts thereof, and hydrates and solvates thereof as active ingredients.
  • the above-mentioned substance itself may be administered as the medicament of the present invention, but it is preferably administered as an oral or parenteral pharmaceutical composition for systemic administration that can be produced by methods well known to those skilled in the art. Can do.
  • the pharmaceutical composition suitable for oral administration include tablets, capsules, powders, fine granules, granules, liquids, and syrups.
  • the pharmaceutical composition suitable for parenteral administration includes For example, injections, suppositories, inhalants, transdermal absorbents, and the like can be mentioned.
  • the above-mentioned retinoid solution is locally sprayed or applied to the internal organs and surrounding tissues as needed during surgery, or locally applied to organs and tissues. It is also possible to employ local administration means such as injection.
  • the above pharmaceutical composition can be produced by adding pharmacologically and pharmaceutically acceptable additives.
  • pharmacologically and pharmaceutically acceptable additives include, for example, excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, dyes, diluents, bases, and dissolution.
  • examples include agents or solubilizers, isotonic agents, pH adjusters, stabilizers, propellants, and pressure-sensitive adhesives.
  • the dosage of the pharmaceutical agent of the present invention is not particularly limited, and can be appropriately increased or decreased according to various factors that should normally be considered, such as patient weight and age, disease type and symptoms, and administration route.
  • it can be used in the range of about 0.01 to 1,000 mg per day for an adult.
  • it can be used in the range of 0.1 mg to 10 mg per adult day.
  • the above dose can be increased or decreased as appropriate.
  • Adhesive ileus was prepared using male or female Wistar rats (about 200 g). After fasting for 24 hours, DNBS (2,4-dinitorobenzenesulfonic acid, 30 mg in 0.5 ml ethanol 30%) was enema injected from the anus.
  • a medicament of the present invention 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl] benzoic acid (generic name “Tamivaloten”) 0.3 mg each group / kg, 1 mg / kg, 3 mg / kg, as a comparative example (positive control drug), salazosulfapyridine (SASP), a commercially available ulcerative colitis treatment drug, was adjusted to 300 mg / kg respectively.
  • Administration was performed once a day for 5 days, 24 hours before and 2 hours before enema, and 24 hours after enema. Tamibarotene and SASP were suspended orally in 0.5% carboxymethylcellulose (Carboxymethylcellulose).
  • the solvent was administered once a day for 5 days 24 hours before and 2 hours before DNBS enema and 24 hours after enema. Necropsy was performed 24 hours after the last administration and the presence or absence of intestinal adhesion was observed.
  • One group of 5 rats was used for each of the tamibarotene administration group, the SASP administration group, the normal group, and the control group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur un médicament devant être administré par voie systémique pour prévenir et/ou traiter une fusion viscérale. Ce médicament contient un composé représenté par la formule générale suivante (I) ou son sel en tant que principe actif. Dans la formule (I), R1 à R5 représentent chacun un atome d'hydrogène, un groupe alkyle ou un groupe silyle alkylé; X représente -CONH- ou -NHCO-; et A représente un groupe aromatique carboxylé qui peut avoir un substituant ou un groupe tropolonyle qui peut avoir un substituant.
PCT/JP2008/052393 2008-02-14 2008-02-14 Médicament pour prévenir et/ou traiter une fusion viscérale Ceased WO2009101684A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2008/052393 WO2009101684A1 (fr) 2008-02-14 2008-02-14 Médicament pour prévenir et/ou traiter une fusion viscérale
JP2009553303A JPWO2009101684A1 (ja) 2008-02-14 2008-02-14 内臓癒着の予防及び／又は治療のための医薬

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2008/052393 WO2009101684A1 (fr) 2008-02-14 2008-02-14 Médicament pour prévenir et/ou traiter une fusion viscérale

Publications (1)

Publication Number Publication Date
WO2009101684A1 true WO2009101684A1 (fr) 2009-08-20

Family

ID=40956728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052393 Ceased WO2009101684A1 (fr) 2008-02-14 2008-02-14 Médicament pour prévenir et/ou traiter une fusion viscérale

Country Status (2)

Country Link
JP (1) JPWO2009101684A1 (fr)
WO (1) WO2009101684A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
JP2003192594A (ja) * 2001-12-27 2003-07-09 Nippon Kayaku Co Ltd 創傷治癒時の障害の治療剤または予防剤
WO2004069276A1 (fr) * 2003-02-05 2004-08-19 Mizuo Miyazaki Medicament pour la prevention, la regulation ou le traitement de l'adherence
WO2007029760A1 (fr) * 2005-09-09 2007-03-15 R & R Inc. Produit pharmaceutique à utiliser dans la prévention et/ou le traitement d’affections abdominales

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
JP2003192594A (ja) * 2001-12-27 2003-07-09 Nippon Kayaku Co Ltd 創傷治癒時の障害の治療剤または予防剤
WO2004069276A1 (fr) * 2003-02-05 2004-08-19 Mizuo Miyazaki Medicament pour la prevention, la regulation ou le traitement de l'adherence
WO2007029760A1 (fr) * 2005-09-09 2007-03-15 R & R Inc. Produit pharmaceutique à utiliser dans la prévention et/ou le traitement d’affections abdominales

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HASHIMOTO, Y. ET AL.: "Retinobenzoic acids and nuclear retinoic acid receptors", CELL STRUCTURE AND FUNCTION, vol. 16, no. 2, 1991, pages 113 - 123, XP008116558, DOI: doi:10.1247/csf.16.113 *

Also Published As

Publication number Publication date
JPWO2009101684A1 (ja) 2011-06-02

Similar Documents

Publication Publication Date Title
US8168677B2 (en) Method for treatment of inflammatory bowel disease
AU2007281212B2 (en) Non-flushing niacin analogues, and methods of use thereof
WO2008070129A2 (fr) Compositions et procédés pour le traitement de maladie inflammatoire
AU2023202321B2 (en) Use of thyroid beta-agonists
JP2008534601A5 (fr)
TW585762B (en) Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases
MX2014000971A (es) Agente mejorador de la funcion diastolica ventricular izquierda.
NZ536493A (en) Medicament comprising a retinoid for therapeutic treatment of vascular disease
JP2002534477A (ja) メラガトランの新規使用
AU2017252126B2 (en) Use of thyroid beta-agonists
RU2250103C2 (ru) ПРИМЕНЕНИЕ (R)-АРИЛПРОПИОНОВЫХ КИСЛОТ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЛЮДЕЙ И ЖИВОТНЫХ, НА КОТОРЫЕ МОЖНО ОКАЗЫВАТЬ ТЕРАПЕВТИЧЕСКОЕ ВОЗДЕЙСТВИЕ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВАЦИИ NF-κВ
JP2008179570A (ja) 内臓癒着の予防及び／又は治療のための医薬
US8431613B2 (en) Memory fixation accelerator
WO2009101684A1 (fr) Médicament pour prévenir et/ou traiter une fusion viscérale
JP3633614B2 (ja) フィブリノーゲン低下剤としてのα，ω−ジカルボン酸の使用
JPWO2008105181A1 (ja) 下部尿路症状の予防及び／又は治療のための医薬
JP3587247B2 (ja) 炎症性腸疾患の予防・治療剤
JP2004535457A (ja) ピリダジノン誘導体の新しい用途
JP2002514208A (ja) 痴呆の治療及び予防におけるシクロオキシゲナーゼ−２阻害剤の使用方法
HK40031604A (en) Methods of administering intravenous meloxicam pre-operatively and in combination with other drugs
JP2000086517A (ja) アロディニア治療剤
JP2008074799A (ja) 白内障の予防及び／又は治療のための医薬
HK1138199A (en) Pharmaceutical agent for prevention and/or treatment of lower urinary tract symptom

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711235

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009553303

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711235

Country of ref document: EP

Kind code of ref document: A1